

Accepted Manuscript

SCA Tethering-PCR: A Rapid Genetic Test for the Diagnosis of SCA1–3, 6, and 7 by PCR and Capillary Electrophoresis

Claudia Cagnoli, Alessandro Brussino, Cecilia Mancini, Marina Ferrone, Laura Orsi, Paola Salmin, Patrizia Pappi, Elisa Giorgio, Elisa Pozzi, Simona Cavalieri, Eleonora Di Gregorio, Marta Ferrero, Alessandro Filla, Giuseppe De Michele, Cinzia Gellera, Caterina Mariotti, Suran Nethisinghe, Paola Giunti, Giovanni Stevanin, Alfredo Brusco



PII: S1525-1578(17)30389-6

DOI: [10.1016/j.jmoldx.2017.12.006](https://doi.org/10.1016/j.jmoldx.2017.12.006)

Reference: JMDI 670

To appear in: *The Journal of Molecular Diagnostics*

Accepted Date: 19 December 2017

Please cite this article as: Cagnoli C, Brussino A, Mancini C, Ferrone M, Orsi L, Salmin P, Pappi P, Giorgio E, Pozzi E, Cavalieri S, Di Gregorio E, Ferrero M, Filla A, De Michele G, Gellera C, Mariotti C, Nethisinghe S, Giunti P, Stevanin G, Brusco A, SCA Tethering-PCR: A Rapid Genetic Test for the Diagnosis of SCA1–3, 6, and 7 by PCR and Capillary Electrophoresis, *The Journal of Molecular Diagnostics* (2018), doi: 10.1016/j.jmoldx.2017.12.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

SCA TETHERING-PCR: A RAPID GENETIC TEST FOR THE DIAGNOSIS OF SCA1-3, 6, AND 7 BY PCR AND CAPILLARY ELECTROPHORESIS

Claudia Cagnoli,* Alessandro Brussino,* Cecilia Mancini,* Marina Ferrone,*† Laura Orsi,‡ Paola Salmin,† Patrizia Pappi,† Elisa Giorgio,* Elisa Pozzi,* Simona Cavalieri,* Eleonora Di Gregorio,* Marta Ferrero,* Alessandro Filla,§ Giuseppe De Michele,§ Cinzia Gellera,¶ Caterina Mariotti,¶ Suran Nethisinghe,|| Paola Giunti,|| Giovanni Stevanin,**††‡‡§§¶¶ and Alfredo Brusco*†

From the Department of Medical Sciences,* University of Turin, Turin, Italy; the Medical Genetics Unit, † Città della Salute e della Scienza University Hospital, Turin, Italy; the Neurologic Division I,‡ Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy; the Department of Neurosciences, Odontostomatological and Reproductive Sciences,§ University Federico II, Naples, Italy; the Unit of Genetics of Neurodegenerative and Metabolic Diseases,¶ Fondazione IRCCS Istituto Neurologico “Carlo Besta”, 20133 Milan, Italy; the Ataxia Centre,|| Department of Molecular Neuroscience, Institute of Neurology, University College London, London, United Kingdom; INSERM,** U 1127, Institut du Cerveau et de la Moelle épinière, Paris, France ; the Centre National de la Recherche Scientifique UMR 7225,†† Paris, France ; UMRS 1127,‡‡ Université Pierre et Marie Curie (Paris 06), Sorbonne Universités, Paris, France; the Ecole Pratique des Hautes Etudes,§§ PSL Research University, 75014, Paris, France ; and the Centre de Référence de Neurogénétique,¶¶ Hôpital de la Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, Paris, France

Funding: Supported by MURST local research (A.Brusco.). S.N. and P.G. work at University College London Hospitals/University College London, which receives a proportion of funding from the Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme.

Corresponding author: Alfredo Brusco, University of Torino, Department of Medical Sciences, via Santena 19, 10126, Torino, Italy. Fax +390116706582; e-mail: alfredo.brusco@unito.it

Footnote: C.Ca. and A.Bruss. contributed equally.

Disclosures: Patent pending for application number: BIT19115-CF, “Genetic test for diagnosing SCA1, 2, 3, 6, and 7”, for A.Brusc., A.Bruss., and C.C.

Running head: SCA1, 2, 3, 6, and 7 diagnostic testing.

ACCEPTED MANUSCRIPT

ABSTRACT

Spinocerebellar ataxias (SCA) type 1, 2, 3, 6, and 7, associated with a (CAG)_n repeat expansion in coding sequences, are the most prevalent autosomal dominant ataxias worldwide (approximately 60% of the cases). In addition, the phenotype of SCA2 expansions has been now extended to Parkinson's disease and amyotrophic lateral sclerosis. Their diagnosis is presently based on a PCR to identify small expanded alleles, followed by a second-level test whenever the suspect of false normal homozygous, or a CAT interruption in SCA1 needs to be verified. Next-generation sequencing still does not allow efficient detection of these repeats. Here, we show the efficacy of a novel, rapid, and cost-effective method to identify and size pathogenic expansions in SCA1-3, 6, and 7 and recognize large alleles or interruptions without a second-level test. Twenty-five healthy controls and 33 expansion carriers were analyzed: alleles migrated consistently in different PCRs/capillary runs, and homozygous subjects were always distinguishable from heterozygous carriers of both common and large (>100 repeats) pathogenic CAG expansions. Repeat number could be calculated counting the number of peaks, except for the largest SCA2 and SCA7 alleles. Interruptions in SCA1 were always visible. Overall, our method allows a simpler, cost-effective, and sensibly faster SCA diagnostic protocol compared to the standard technique and to the still unadapted next-generation sequencing.

INTRODUCTION

Autosomal dominant cerebellar ataxias (SCA) are clinically and genetically heterogeneous neurodegenerative diseases characterized by the progressive loss of voluntary muscle control (ataxia) often associated with various neurological and extra-neurological signs, and cerebellar atrophy. In two-thirds of all SCA patients, gait disorders are the prevalent symptoms at onset, and the first signs of disease appear in the third-fourth decade of life.¹

The classification based on clinical signs and symptoms, originally proposed by Anita Harding² does not allow the discrimination of subtypes as: i) different subtypes share common phenotypic features; ii) clinical signs vary considerably between families with the same subtype; iii) extra-cerebellar clinical manifestations can be the predominant signs of the disease; iv) complicated forms can show extra-cerebellar signs only in the advanced stages of the disease.³ Presently, a classification based on the gene/locus associated with the disease is preferred:⁴ at the time of writing, more than 35 SCA subtypes have been identified, and the underlying genetic mutation is known for at least 29 of them (<http://neuromuscular.wustl.edu/ataxia/domatax.html>, last accessed November 17, 2017).

Mutations can be divided in expansions/insertions of a polynucleotide repeat (SCA1–3, SCA6–8, SCA10, SCA12, SCA17, SCA31, SCA36 and dentato-rubro-pallidoluysian atrophy/DRPLA), and conventional mutations.⁵⁻⁷ It has been suggested that the most severe and complicated forms belong to the first group whereas the second includes mostly pure forms of ataxia.^{6,8} SCA1 (MIM#164400), SCA2 (OMIM#183090), SCA3 (OMIM#109150), SCA6 (OMIM#183086), SCA7 (OMIM#164500), SCA17 (OMIM#607136), and DRPLA (OMIM#125370) belong to the group of (CAG)_n repeat expansions in coding sequences. The mutation causes the polyglutamine-encoded tract to exceed a pathogenic threshold specific for each protein.⁹

In three genes, the CAG-tract can be interrupted: in SCA1, by CAT units, encoding for histidine; in SCA2 and SCA17, by CAA units, coding for the glutamine amino acid. The length and position of these interruptions is variable within the CAG-tract, and alleles carrying interruptions are less prone to meiotic

expansion. Furthermore, SCA1 expanded alleles with 39 to 44 repeats are not pathogenic in the presence of interruptions.¹⁰ In SCA2, small interrupted repeat expansions and interrupted intermediate-size repeats have been associated with Parkinson disease and amyotrophic lateral sclerosis, respectively, in numerous studies.¹¹⁻¹⁵ A recent large survey, however, did not find any correlation between SCA2, 3, 6, and 17 expansions and Parkinson disease.¹⁶

Taken together, SCA1-3, 6, and 7 are the most prevalent autosomal dominant ataxias worldwide, accounting for ~60% of the cases.^{5, 17-28} The diagnosis of these SCAs is presently based on a standard PCR able to identify small-expanded alleles, followed by a second-level test whenever an interruption in SCA1 is to be verified or the PCR shows a single allele in a symptomatic subject (false homozygous), raising the question if an expanded allele failed to be amplified.²⁹

Here, we show the efficacy of a novel, rapid, and cost-effective method based on PCR and capillary electrophoresis, named tethering PCR (tPCR), to identify and size pathogenic expansions in SCA1-3, 6 and 7 and recognize large alleles or interruptions without a second-level test. This method advances our previous technique to detect large SCA2 and SCA7 expansions³⁰ and is required for efficient and reliable diagnosis as next-generation sequencing (NGS) techniques still fail to detect these repeats.

MATERIALS AND METHODS

Twenty-five healthy controls, tested negative for SCA1-3, 6, and 7 using a standard diagnostic technique (based on PCR amplification and CAG-repeat assessment using the amplicon size as a reference), and 33 expansion carriers (SCA1, n=9; SCA2, n=8; SCA3, n=4; SCA6 n=6; SCA7, n=6) were collected at the “Città della Salute e della Scienza” University Hospital of Torino, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, the Pitié-Salpêtrière University Hospital of Paris according to local ethical rules (Department of Medical Sciences, Istituto Neurologico “Carlo Besta” and Paris-Necker Ethics Committees) (Table 1). Blood samples were obtained with the written consent of the subjects, and DNA was extracted using standard procedures.

Expansion carriers were diagnosed using standard PCR, a combination of standard PCR and Southern blot for the larger alleles, or a combination of PCR and enzymatic digestion to assess the presence of CAT interruption in SCA1 expanded alleles (Table 2).³¹

To precisely assess the number of CAG repeats, seven subjects to have two homozygous controls, carrying the more common allele according to literature data, for SCA1, 3, 6, and 7, and a homozygous (allele size = 22 CAG) and a heterozygous (allele size = 22/23 CAG) subject for SCA2 (Table 1) were Sanger-sequenced. Three of these subjects (CTR1, CTR5, and CTR15; Table 1) were also used to verify the reproducibility of amplicon size. Each sample used for the set-up was PCR-amplified five times, the first PCR was run five times (capillary replicates), and PCRs 2nd-5th were run once (PCR replicates).

A locus-specific fluorescently labeled forward primer was designed for each SCA upstream of the unstable repeat. The reverse primer contained a locus-specific sequence followed by five CTG units complementary to the (CAG)_n repeats (Table 3, Figure 1). This design allows: i) the amplification of the entire repeat, obtaining amplicons of different sizes for each SCA (SCA1 = PET, 104-200 bp; SCA2 = ATTO, 255-327 bp; SCA3 = FAM, 170-272 bp; SCA6 = VIC, 70-108 bp; SCA7 = FAM, 115-157 bp; sizes are referred to alleles in the normal range); ii) the random annealing inside the unstable sequence, generating a stutter of bands starting from five/nine CAG repeats and differing from each other by one repeat (Figure 1). This is useful for manually counting the repeats number and can allow automatic binning.

Amplifications were performed using different combinations of MgCl₂ (Promega, Madison, WI), Betaine (Sigma-Aldrich, Milan, Italy), DMSO 100% (Sigma-Aldrich), and GoTaq G2 Hot-start polymerase with Flexi Buffer (Promega) as reported in Table 4, on a Biometra T Professional or a Biometra T Gradient thermal cycler (Analytik Jena, Jena, Germany). PCR products were subsequently pooled in two groups (SCA1, 3, 6 and SCA2, 7) and loaded on an ABI Prism 3730XL automatic sequencer (Thermo Fisher Scientific, Foster City, CA) on a 36 cm capillary with the POP7 polymer and the GS-500 Liz size-standard. Oven temperature was set to 60 °C, injection voltage to 2.5 kV, and injection time to 20 sec.

The bioinformatics analysis was performed using the GeneMapper ver4.0 (Thermo Fisher Scientific) and GeneMarker ver.1.95 (Softgenetics, State College, PA) software by three independent operators.

RESULTS

The rationale to set up a rapid technique for the diagnosis of the main SCAs associated with polyglutamine expansions (SCA1-3, 6, and 7), was to minimize the number of PCR reactions, thermal cycling conditions, and capillary electrophoresis runs. Different combinations of commercially available reagents, and co-solvents commonly used to amplify CG-rich regions (eg, Betaine and DMSO) were tested. The optimal conditions and mix of reagents for each SCA are reported in Table 4 and 5 and in the *Materials and Methods*. As a final procedure, three different chemical protocols (SCA2 and SCA7 required specific concentrations of DMSO and MgCl₂ compared to SCA1, 3, and 6), and a single cycling condition were used to amplify all five SCAs.

To determine the exact number of repeats for each tested SCA, and have the standard profile of a homozygous subject, one homozygous genotype was selected for each SCA allele in the normal range. These SCA alleles were Sanger-sequenced to be used as calibrators in subsequent reactions. The size of the alleles was deduced from the number of peaks in the arrays as specified below. In both capillary electrophoresis and PCR replicates, the same allele migrated consistently, with a standard deviation \leq 0.41 base pair (Supplemental Table S1).

Then, 25 healthy controls and 33 expansion carriers were tested using this method. Electropherograms showed a series of discrete peaks: using the three calibrators, the first peak corresponded to five CAG repeats for SCA1, 2, 6, and 7, and to nine CAG repeats for SCA3 (Figure 2, 3). Each subsequent peak corresponded to an increment of one CAG repeat. The average distance between two consecutive peaks was ~2.9 bp, slightly smaller than the expected 3 bp (one CAG-repeat).

Peaks with the highest intensity corresponded to the size of the genotyped allele(s).

A homozygous subject was always distinguishable from a heterozygous carrier of an expansion (Figures 2, 3). If the expansion was $< \sim 100$ repeats, the second allele was detectable as a bell-shaped array of peaks for SCA1, 2, 3, and 7: the tallest peak within the bell was considered for allele-calling (Figure 3). In SCA6, the small size of the pathological expansion prevented the formation of the bell-shaped curve (Figure 3). The hallmark for large SCA2 and SCA7 expansions (> 100 CAGs) was a slowly degrading array of peaks (Figure 3): the size of the larger allele could not be determined by our technique.

Sizes detected by our method and the standard PCR technique in controls and expansion carriers were compared (Table 1 and 2). A systematic difference in SCA1 was found (-1 to -3 repeats). In these cases, the presence of CAT interruptions could be clearly determined as a gap in the array of peaks (Figure 2). In SCA2, the measure was concordant with the standard PCR (Table 1 and 2). A very large SCA2 expansion carrier (EXP11, ~ 200 CAG as estimated by Southern blot³²) was recognizable by the descending array of peaks starting from the normal allele (Figure 3). The presence of a CAA-interrupted allele was always clearly detectable (Figure 2 and 3).

In SCA3, the standard PCR overestimated the CAG-repeat size of the smaller allele by one unit in 11 controls (Table 1). In the four expansion carriers, both the normal and the expanded allele were over- or underestimated by the standard PCR by 1-4 CAG (Table 2). Using the standard diagnostic technique, one out of four expanded alleles (EXP20, Table 2) fell out of the ± 3 tolerance recommended by the European Molecular Genetics Quality Network (EMQN) guidelines.

In SCA6, the standard PCR overestimated the CAG-repeat size by one unit in four out of 25 controls (Table 1). The sizing of expanded alleles using our technique was precise, as recommended by the EMQN guidelines (± 1 CAG).

In SCA7, the standard PCR overestimated one control and one expanded allele by one CAG unit. (Table 2). The three large expansions (EXP31, 32, and 33) were estimated by Southern blot analysis^{33, 34}, and were always recognizable with our technique because of the descending array of peaks starting from the normal allele (Figure 3).

DISCUSSION

Here, we describe a new method to determine the presence of pathogenic expanded SCA1-3, 6, and 7 alleles, named tethering-PCR. To go beyond the standard PCR method and the STR-primed PCR technique developed in our laboratory for several triplet expansion disorders,^{30, 35, 36} a SCA testing protocol was implemented, following the procedure described for Huntington's disease.³⁷ In this protocol, a forward fluorescent-labeled primer was coupled with a reverse primer containing the last five CTG units of the polyglutamine encoding repeat followed by 15 to 16 bp of the gene-specific region. After the capillary run, an array of peaks was obtained and interpreted.

The test overcomes several limits of the standard diagnostic technique, which is performed amplifying the region containing the repeat with primers external to the CAG-tract and measuring the amplicon after capillary electrophoresis. Moreover, in the STR-primed PCR the reverse primer anneals in the repeat only, and a third primer, annealing on the reverse's tail, is required for the final amplification. Although this allows the formation of an array of stutter bands, the normal alleles are not clearly distinguishable, a precise CAG-size counting is not possible, and interruptions in SCA1 and SCA2 are not visible.

The size of the alleles measured using the formula

$$[(\text{amplicon size} - \text{"constant region"})/3]$$

is incorrect. Allele migration is influenced by the fluorochrome in the labeled primer, the type of capillary, the polymer, and the presence of the repeat itself. Thus, the "constant region" size needs to be corrected experimentally, running a known control sample validated by Sanger sequencing. Moreover, the sizing error increases with the number of repeats, as also shown for other triplet repeat disorders.³⁶ In this work, an average distance between two CAG-consecutive peaks of ~2.9 bp was calculated, instead of the expected 3 bp, causing an error in the measure of CAG-alleles that increases with their size. With this

method, allele sizing is performed counting the number of peaks, each corresponding to a CAG unit, starting from the first visible one. However, since SCA1 and SCA2 interrupted alleles contain traits in which the peaks are not visible, it would still be advisable to run a standard sample whose CAG-repeat number has been ascertained by Sanger sequencing, and/or to generate a sizing bin based on the carrier of an uninterrupted expansion allele, in which all peaks are visible. The first peak corresponded to five CAGs for SCA1, 2, 6, and 7, as was expected because the reverse primer contains five CTG units. For SCA3, the first peak corresponded to nine CAGs: this is because SCA3 polyglutamine trait starts with an “irregular” and interrupted CAGCAGCAAAG sequence, encoding for the amino acids Glu-Glu-Glu-Lys and included in the count of CAG repeats³⁸. The reverse primer is most likely unable to anneal because of the mismatches, skips these four units, and then anneals from the fifth to the ninth CAG, producing a first peak corresponding to nine CAG units (Supplemental Figure S1).

The standard technique cannot discriminate between homozygous alleles and an expansion carrier with a dropped-out allele. Indeed, standard PCR in triplet repeat disorders is unable to amplify large alleles due to technical limitations.^{36, 39-41} Large alleles have been described in SCA2 neonatal and infantile-onset cases (230-500 CAG repeats),⁴²⁻⁴⁴ and in SCA7 severe forms with onset in childhood and a rapid fatal course (55-460 CAG repeats).^{33, 45-49} It is therefore mandatory to perform a second-level test (eg, Southern blot) when a homozygous genotype is found in infantile cases or in prenatal tests where one of the parents is a carrier. With this method, carriers of an expanded allele, the size of which falls out of the PCR sensitivity range, are clearly discernible from normal homozygous subjects because of the presence of a slowly descending array of peaks starting from the main one. This array is never found on a normal subject (Figures 2 and 3). In carriers of smaller expansions, the expanded allele is visible as a bell-shaped array of peaks for SCA1-3, and 7. In SCA6, such an array does not form due to the small number of repeats even in pathologically expanded alleles and it is sufficient to count the number of peaks.

This method is able to clearly detect both SCA1 and SCA2 interruptions (Figure 2 and 3). In routine diagnostics, when a SCA1 allele between 36 to 44 CAG repeats is found, a second level test to determine

the presence of CAT interruptions is used to discriminate if the allele is not associated with the disease (interrupted), is a mutable normal allele (36 to 38 non-interrupted CAGs), or is a full-penetrance allele (39 to 44 non-interrupted CAGs). Moreover, recent findings strongly suggest the association of SCA2 interrupted intermediate alleles with amyotrophic lateral sclerosis.

In conclusion, the current diagnostic procedure for polyglutamine expanded SCAs is time-consuming and requires distinct amplification protocols, PCR conditions, and capillary runs. Having the same thermal cycling protocol, our new method allows the simultaneous amplification of five SCAs on a single thermal cycler. Primer design allows two pooled runs for the capillary electrophoresis. These features lead to a simpler, cost-effective, and significantly faster SCA diagnostic protocol compared to the standard technique.

References

1. Globas C, du Montcel ST, Baliko L, Boesch S, Depondt C, DiDonato S, Durr A, Filla A, Klockgether T, Mariotti C, Melegh B, Rakowicz M, Ribai P, Rola R, Schmitz-Hubsch T, Szymanski S, Timmann D, Van de Warrenburg BP, Bauer P, Schols L: Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. *Mov Disord* 2008, 23:2232-2238
2. Harding AE, Muller DP, Thomas PK, Willison HJ: Spinocerebellar degeneration secondary to chronic intestinal malabsorption: a vitamin E deficiency syndrome. *Ann Neurol* 1982, 12:419-424
3. Rossi M, Perez-Lloret S, Doldan L, Cerquetti D, Balej J, Millar Verneti P, Hawkes H, Cammarota A, Merello M: Autosomal dominant cerebellar ataxias: a systematic review of clinical features. *Eur J Neurol* 2014, 21:607-615
4. Vallat JM, Goizet C, Tazir M, Couratier P, Magy L, Mathis S: Classifications of neurogenetic diseases: An increasingly complex problem. *Rev Neurol (Paris)* 2016, 172:339-349
5. Schols L, Bauer P, Schmidt T, Schulte T, Riess O: Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. *Lancet Neurol* 2004, 3:291-304
6. Durr A: Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. *Lancet Neurol* 2010, 9:885-894
7. Matilla-Duenas A, Ashizawa T, Brice A, Magri S, McFarland KN, Pandolfo M, Pulst SM, Riess O, Rubinsztein DC, Schmidt J, Schmidt T, Scoles DR, Stevanin G, Taroni F, Underwood BR, Sanchez I: Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. *Cerebellum* 2014, 13:269-302
8. Coutelier M, Coarelli G, Monin ML, Konop J, Davoine CS, Tesson C, Valter R, Anheim M, Behin A, Castelnovo G, Charles P, David A, Ewenczyk C, Fradin M, Goizet C, Hannequin D, Labauge P, Riant F, Sarda P, Sznajer Y, Tison F, Ullmann U, Van Maldergem L, Mochel F, Brice A, Stevanin G, Durr A: A panel study on patients with dominant cerebellar ataxia highlights the frequency of channelopathies. *Brain* 2017, 140:1579-1594
9. Stevanin G, Durr A, Brice A: Clinical and molecular advances in autosomal dominant cerebellar ataxias: from genotype to phenotype and physiopathology. *Eur J Hum Genet* 2000, 8:4-18
10. Kraus-Perrotta C, Lagalwar S: Expansion, mosaicism and interruption: mechanisms of the CAG repeat mutation in spinocerebellar ataxia type 1. *Cerebellum Ataxias* 2016, 3:20
11. Charles P, Camuzat A, Benammar N, Sellal F, Destee A, Bonnet AM, Lesage S, Le Ber I, Stevanin G, Durr A, Brice A: Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? *Neurology* 2007, 69:1970-1975
12. Lattante S, Millecamps S, Stevanin G, Rivaud-Pechoux S, Moigneu C, Camuzat A, Da Barroca S, Mundwiller E, Couarch P, Salachas F, Hannequin D, Meininger V, Pasquier F, Seilhean D, Couratier P, Danel-Brunaud V, Bonnet AM, Tranchant C, LeGuern E, Brice A, Le Ber I, Kabashi E: Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. *Neurology* 2014, 83:990-995
13. Sproviero W, Shatunov A, Stahl D, Shoai M, van Rheenen W, Jones AR, Al-Sarraj S, Andersen PM, Bonini NM, Conforti FL, Van Damme P, Daoud H, Del Mar Amador M, Fogh I, Forzan M, Gaastra B, Gellera C, Gitler AD, Hardy J, Fratta P, La Bella V, Le Ber I, Van Langenhove T, Lattante S, Lee YC, Malaspina A, Meininger V, Millecamps S, Orrell R, Rademakers R, Robberecht W, Rouleau G, Ross OA, Salachas F, Sidle K, Smith BN, Soong BW, Soraru G, Stevanin G, Kabashi E, Troakes C, van Broeckhoven C, Veldink JH, van den Berg LH, Shaw CE, Powell JF, Al-Chalabi A: ATXN2 trinucleotide repeat length correlates with risk of ALS. *Neurobiol Aging* 2017, 51:178 e171-178 e179

14. Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, Elman L, Kalb RG, Trojanowski JQ, Lee VM, Van Deerlin VM, Gitler AD, Bonini NM: PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. *PLoS One* 2011, 6:e17951
15. Corrado L, Mazzini L, Oggioni GD, Luciano B, Godi M, Brusco A, D'Alfonso S: ATXN-2 CAG repeat expansions are interrupted in ALS patients. *Hum Genet* 2011, 130:575-580
16. Wang L, Aasly JO, Annesi G, Bardien S, Bozi M, Brice A, Carr J, Chung SJ, Clarke C, Crosiers D, Deutschlander A, Eckstein G, Farrer MJ, Goldwurm S, Garraux G, Hadjigeorgiou GM, Hicks AA, Hattori N, Klein C, Jeon B, Kim YJ, Lesage S, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pihlstrom L, Pramstaller PP, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Silburn PA, Theuns J, Tan EK, Tomiyama H, Toft M, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore DM, Kruger R, Sharma M: Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. *Neurology* 2015, 85:1283-1292
17. Schols L, Amoiridis G, Buttner T, Przuntek H, Epplen JT, Riess O: Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? *Ann Neurol* 1997, 42:924-932
18. Moseley ML, Benzow KA, Schut LJ, Bird TD, Gomez CM, Barkhaus PE, Blindauer KA, Labuda M, Pandolfo M, Koob MD, Ranum LP: Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. *Neurology* 1998, 51:1666-1671
19. Saleem Q, Choudhry S, Mukerji M, Bashyam L, Padma MV, Chakravarthy A, Maheshwari MC, Jain S, Brahmachari SK: Molecular analysis of autosomal dominant hereditary ataxias in the Indian population: high frequency of SCA2 and evidence for a common founder mutation. *Hum Genet* 2000, 106:179-187
20. Storey E, du Sart D, Shaw JH, Lorentzos P, Kelly L, McKinley Gardner RJ, Forrest SM, Biros I, Nicholson GA: Frequency of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with spinocerebellar ataxia. *Am J Med Genet* 2000, 95:351-357
21. Tang B, Liu C, Shen L, Dai H, Pan Q, Jing L, Ouyang S, Xia J: Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. *Arch Neurol* 2000, 57:540-544
22. Maruyama H, Izumi Y, Morino H, Oda M, Toji H, Nakamura S, Kawakami H: Difference in disease-free survival curve and regional distribution according to subtype of spinocerebellar ataxia: a study of 1,286 Japanese patients. *Am J Med Genet* 2002, 114:578-583
23. Silveira I, Miranda C, Guimaraes L, Moreira MC, Alonso I, Mendonca P, Ferro A, Pinto-Basto J, Coelho J, Ferreira F, Poirier J, Parreira E, Vale J, Janeiro C, Barbot C, Tuna A, Barros J, Koide R, Tsuji S, Holmes SE, Margolis RL, Jardim L, Pandolfo M, Coutinho P, Sequeiros J: Trinucleotide repeats in 202 families with ataxia: a small expanded (CAG)_n allele at the SCA17 locus. *Arch Neurol* 2002, 59:623-629
24. van de Warrenburg BP, Sinke RJ, Verschuuren-Bemelmans CC, Scheffer H, Brunt ER, Ippel PF, Maat-Kievit JA, Dooijes D, Notermans NC, Lindhout D, Knoers NV, Kremer HP: Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. *Neurology* 2002, 58:702-708
25. Shimizu Y, Yoshida K, Okano T, Ohara S, Hashimoto T, Fukushima Y, Ikeda S: Regional features of autosomal-dominant cerebellar ataxia in Nagano: clinical and molecular genetic analysis of 86 families. *J Hum Genet* 2004, 49:610-616
26. Zortea M, Armani M, Pastorello E, Nunez GF, Lombardi S, Tonello S, Rigoni MT, Zuliani L, Mostacciolo ML, Gellera C, Di Donato S, Trevisan CP: Prevalence of inherited ataxias in the province of Padua, Italy. *Neuroepidemiology* 2004, 23:275-280

27. Jiang M, Jin CL, Lin CK, Qiu GR, Liu ZL, Wang CX, Sun KL: [Analysis and application of SCA1 and SCA3/MJD gene CAG repeats in Han population in Northeastern China]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2004, 21:83-85
28. Brusco A, Gellera C, Cagnoli C, Saluto A, Castucci A, Michielotto C, Fetoni V, Mariotti C, Migone N, Di Donato S, Taroni F: Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. *Arch Neurol* 2004, 61:727-733
29. Sequeiros J, Martindale J, Seneca S, Giunti P, Kamarainen O, Volpini V, Weirich H, Christodoulou K, Bazak N, Sinke R, Sulek-Piatkowska A, Garcia-Planells J, Davis M, Frontali M, Hamalainen P, Wieczorek S, Zuhlke C, Saraiva-Pereira ML, Warner J, Leguern E, Thonney F, Quintans Castro B, Jonasson J, Storm K, Andersson A, Ravani A, Correia L, Silveira I, Alonso I, Martins C, Pinto Basto J, Coutinho P, Perdigao A, Barton D, Davis M, European Molecular Quality Genetics N: EMQN Best Practice Guidelines for molecular genetic testing of SCAs. *Eur J Hum Genet* 2010, 18:1173-1176
30. Cagnoli C, Stevanin G, Michielotto C, Gerbino Promis G, Brussino A, Pappi P, Durr A, Dragone E, Viemont M, Gellera C, Brice A, Migone N, Brusco A: Large pathogenic expansions in the SCA2 and SCA7 genes can be detected by fluorescent repeat-primed polymerase chain reaction assay. *J Mol Diagn* 2006, 8:128-132
31. Koefoed P, Nielsen JE, Hasholt L, Jensen PKA, Fenger K, Sorensen SA: The molecular diagnosis of spinocerebellar ataxia type 1 in patients with ataxia. *Eur J Neurol* 1997, 4:586-592
32. Mao R, Aylsworth AS, Potter N, Wilson WG, Brenningstall G, Wick MJ, Babovic-Vuksanovic D, Nance M, Patterson MC, Gomez CM, Snow K: Childhood-onset ataxia: testing for large CAG-repeats in SCA2 and SCA7. *Am J Med Genet* 2002, 110:338-345
33. Benton CS, de Silva R, Rutledge SL, Bohlega S, Ashizawa T, Zoghbi HY: Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype. *Neurology* 1998, 51:1081-1086
34. Stevanin G, Giunti P, Belal GD, Durr A, Ruberg M, Wood N, Brice A: De novo expansion of intermediate alleles in spinocerebellar ataxia 7. *Hum Mol Genet* 1998, 7:1809-1813
35. Cagnoli C, Michielotto C, Matsuura T, Ashizawa T, Margolis RL, Holmes SE, Gellera C, Migone N, Brusco A: Detection of large pathogenic expansions in FRDA1, SCA10, and SCA12 genes using a simple fluorescent repeat-primed PCR assay. *J Mol Diagn* 2004, 6:96-100
36. Saluto A, Brussino A, Tassone F, Arduino C, Cagnoli C, Pappi P, Hagerman P, Migone N, Brusco A: An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene. *J Mol Diagn* 2005, 7:605-612
37. Jama M, Millson A, Miller CE, Lyon E: Triplet repeat primed PCR simplifies testing for Huntington disease. *J Mol Diagn* 2013, 15:255-262
38. Adam MP AH, Pagon RA, et al., editors: Spinocerebellar Ataxia Type 3. *GeneReviews* 1993-2017, Seattle (WA): University of Washington, Seattle:
39. Warner JP, Barron LH, Goudie D, Kelly K, Dow D, Fitzpatrick DR, Brock DJ: A general method for the detection of large CAG repeat expansions by fluorescent PCR. *J Med Genet* 1996, 33:1022-1026
40. Matsuura T, Ashizawa T: Spinocerebellar ataxia type 10: a disease caused by a large ATTCT repeat expansion. *Adv Exp Med Biol* 2002, 516:79-97
41. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, Dalton JC, Ranum LP: Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. *Neurology* 2003, 60:657-664

42. Cancel G, Durr A, Didierjean O, Imbert G, Burk K, Lezin A, Belal S, Benomar A, Abada-Bendib M, Vial C, Guimaraes J, Chneiweiss H, Stevanin G, Yvert G, Abbas N, Saudou F, Lebre AS, Yahyaoui M, Hentati F, Vernant JC, Klockgether T, Mandel JL, Agid Y, Brice A: Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. *Hum Mol Genet* 1997, 6:709-715
43. Riess O, Laccone FA, Gispert S, Schols L, Zuhlke C, Vieira-Saecker AM, Herlt S, Wessel K, Epplen JT, Weber BH, Kreuz F, Chahrokh-Zadeh S, Meindl A, Lunkes A, Aguiar J, Macek M, Jr., Krebsova A, Macek M, Sr., Burk K, Tinschert S, Schreyer I, Pulst SM, Auburger G: SCA2 trinucleotide expansion in German SCA patients. *Neurogenetics* 1997, 1:59-64
44. Moretti P, Blazo M, Garcia L, Armstrong D, Lewis RA, Roa B, Scaglia F: Spinocerebellar ataxia type 2 (SCA2) presenting with ophthalmoplegia and developmental delay in infancy. *Am J Med Genet A* 2004, 124:392-396
45. Martin J, Van Regemorter N, Del-Favero J, Lofgren A, Van Broeckhoven C: Spinocerebellar ataxia type 7 (SCA7) - correlations between phenotype and genotype in one large Belgian family. *J Neurol Sci* 1999, 168:37-46
46. David G, Durr A, Stevanin G, Cancel G, Abbas N, Benomar A, Belal S, Lebre AS, Abada-Bendib M, Grid D, Holmberg M, Yahyaoui M, Hentati F, Chkili T, Agid Y, Brice A: Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). *Hum Mol Genet* 1998, 7:165-170
47. van de Warrenburg BP, Frenken CW, Ausems MG, Kleefstra T, Sinke RJ, Knoers NV, Kremer HP: Striking anticipation in spinocerebellar ataxia type 7: the infantile phenotype. *J Neurol* 2001, 248:911-914
48. Ansoorge O, Giunti P, Michalik A, Van Broeckhoven C, Harding B, Wood N, Scaravilli F: Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats. *Ann Neurol* 2004, 56:448-452
49. Johansson J, Forsgren L, Sandgren O, Brice A, Holmgren G, Holmberg M: Expanded CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation. *Hum Mol Genet* 1998, 7:171-176

FIGURE LEGENDS

Figure 1. Schematic of the proposed PCR procedure. An ideal heterozygous subject, carrying 11 and 12 CAG repeats (small rectangular bars), is represented. The forward primer (F), marked with a fluorochrome (green), is designed to anneal upstream of the repeat. The reverse primer (R) anneals partly on the repeat, and partly downstream. Given this particular design, it can amplify the whole repeat (upper part) generating two main peaks (heterozygous subject), and, at the same time, it can anneal inside the repeat giving rise to a discrete number of stutter bands with a 3 bp interval (lower part). The electropherogram shows two main peaks (11 and 12 CAG repeats from left to right) preceded by an array of smaller peaks starting from five CAG repeats.

Figure 2. The electropherograms of one homozygous and one heterozygous normal subject for each SCA tested are reported. Homozygous subjects' alleles were also sized by Sanger sequencing. Each panel contains the subject code (see also Tables 1 and 2), the allele size (expressed as number of CAG repeats), and the main peak(s) size. SCA1: peaks start from 104 ± 1 bp, corresponding to 5-CAG repeats; SCA2: peaks start from 255 ± 1 bp, corresponding to 5-CAG repeats; SCA3: peaks start from 170 ± 1 bp, corresponding to 9-CAG repeats; SCA6: peaks start from 70 ± 1 bp, corresponding to 5-CAG repeats; SCA7: peaks start from 115 ± 1 bp, corresponding to 5-CAG repeats. Main peaks are marked by a black arrowhead. The size of the first peak is reported only in left panels. The order reflects the two different pools prepared before capillary electrophoresis (SCA1, 3, 6 and SCA2, 7). For SCA1 and SCA2 homozygous subjects, a zoomed panel shows the tract in which peaks are absent because of the presence of CAT and CAA interruption, respectively.

Figure 3. On the left, electropherograms of one expansion carrier for each SCA tested are reported. A black arrowhead indicates the main peak and the peak corresponding to the expanded allele. On the right, two subjects carrying large SCA2 and SCA7 expansions are reported. A black arrowhead indicates the main peak whereas the expanded allele is not visible. A zoomed panel shows a slowly descending array of peaks, the hallmark of the presence of an expanded allele. Each panel contains the subject code (see also Tables 1 and 2), the alleles size (expressed as number of CAG repeats), and peak size. The order reflects the two different pools prepared before capillary electrophoresis (SCA1, 3, 6 and SCA2, 7).

Table 1. Controls (CTR) analyzed for each SCA.

CTR	SCA1		SCA2		SCA3		SCA6		SCA7	
	S	T	S	T	S	T	S	T	S	T
<u>1</u>	28/29	29/30	22/22	=	18/26	=	13/13	13/13	10/10	10/10
2	28/29	29/30	22/22	=	21/21	=	12/13	=	10/10	=
3	29/29*	30/30*	22/22	=	18/19	=	11/11	11/11	10/10	=
4	28/30	29/31	22/22	22/22	13/21	12/21	13/13	=	10/10	=
<u>5</u>	28/28*	29/29*	22/22	=	21/21	21/21	11/12	=	10/10	=
6	28/32	29/33	22/22	=	13/25	12/25	4/11	=	10/10	=
7	28/30	29/31	22/22	=	17/20	=	7/13	=	10/10	=
8	29/32	30/33	22/22	=	13/22	12/21	7/12	=	9/12	=
9	28/30	29/31	22/22	=	13/18	12/18	11/13	=	11/12	10/12
10	28/31	29/32	22/23	=	19/25	=	7/11	=	10/14	=
11	29/29	30/30	22/22	=	13/13*	12/12*	11/13	=	10/10	=
12	28/31	29/32	22/22	=	13/21	12/21	12/13	=	10/13	=
13	29/29	30/30	22/22	=	19/21	=	7/13	=	10/12	=
14	28/29	29/30	22/23	=	19/22	=	7/11	=	10/10	=
<u>15</u>	28/29	29/30	22/23	22/23	13/20	12/20	11/12	=	10/12	=
16	28/28	29/29	22/22	=	13/21	12/21	9/10	10/11	10/13	=
17	28/29	29/30	22/22	=	21/25	=	13/13	=	10/12	=
18	28/32	29/33	22/22	=	18/21	=	7/11	=	10/10	=
19	29/31	30/32	22/22	=	13/22	12/22	10/12	11/13	10/13	=
20	30/31	31/32	22/22	=	15/21	14/21	10/11	11/12	10/12	=
21	28/31	29/32	22/22	=	21/24	=	4/13	=	12/12	12/12
22	26/29	27/30	22/22	=	19/21	=	12/12	=	10/12	=
23	28/31	29/32	22/22	=	13/19	12/19	10/12	11/12	10/10	=
24	28/29	29/30	22/22	=	21/25	=	12/13	=	10/10	=
25	28/29	29/30	22/22	=	13/13	12/12	7/13	=	10/10	=

Allele sizes are expressed as CAG-repeat number. Subjects used to set-up the technique are underlined. Alleles sequenced for SCA2, SCA3, SCA6, and SCA7 for which sPCR and tPCR were concordant are in bold.

*sequenced alleles for which sPCR and tPCR were discordant (SCA1, CTR3 and CTR5, and SCA3, CTR11): in all three cases sPCR under- or over-estimated the number of repeats measured by Sanger sequencing.

S = sPCR (standard PCR); T = tPCR (tether PCR).

Values in "T" columns are indicated with an equal sign (=) when the measures obtained by sPCR and tPCR were identical.

Table 2. Expansion carriers (EXP) analyzed for each SCA.

	EXP	Standard PCR	Tether PCR
SCA1	1	28/56	29/58
	2	29/42	30/44
	3	29/48	30/50
	4	35/53	36/55
	5	31/36	=
	6	28/34	29/37
	7	31/56	30/57
	8	31/51	30/51
	9	29/44	28/44
SCA2	10	22/36	=
	11	23/~200*	=
	12	-	22/41
	13	-	22/36
	14	22/45	=
	15	22/36	=
	16	22/33	=
SCA3	17	22/36	=
	18	22/67	23/70
	19	25/70	24/71
SCA6	20	24/74	20/70
	21	29/65	28/66
SCA7	22	11/23	=
	23	11/23	=
	24	11/23	=
	25	13/23	=
	26	13/22	=
	27	13/24	=
SCA7	28	-	12/34
	29	10/44	=
	30	10/41	10/40
	31	10/~86*	10/90
	32	12/~140*	12/>100
	33	12/~81*	12/85

* Estimated by Southern blot analysis.

Allele sizes are expressed as CAG-repeat number.

Equal sign (=) indicates when the measures obtained by standard and tether were identical. A dash (-) indicates that the subject was not analyzed by standard PCR.

Table 3. Primer sequences.

GENE	FORWARD	REVERSE
<i>SCA1</i>	5'-PET-TTTGCTGGAGGCTATTCCACTCT-3'	5'-GAGCCCTGCTGAGGTGCTGCTGCTGCTGCTG-3'
<i>SCA2</i>	5'-ATTO-TTTCGGCGGCTCCTTGGTCTC-3'	5'-AGCCGCGGGCGGCGGCTGCTGCTGCTGCTG-3'
<i>SCA3</i>	5'-FAM-AGTCCAGTGACTACTTTGATTCG-3'	5'-GTCCTGATAGGTCCCCCTGCTGCTGCTGCTG-3'
<i>SCA6</i>	5'-VIC-TTTTTCCCCTGTGATCCGTAAGG-3'	5'-CGGCCTGGCCACCGCCTGCTGCTGCTGCTG-3'
<i>SCA7</i>	5'-FAM-TTTGAAAGAATGTCGGAGCGGG-3'	5'-CTGCGGAGGCGGCGGCTGCTGCTGCTGCTG-3'



Table 4. PCR Reagents.

Reagent	Quantity (μ L)		
	SCA1, 3, 6	SCA2	SCA7
dNTPs 2.5mM	1.8	1.8	1.8
MgCl ₂ 25mM	1.8	1.8	1.1
Buffer 5X	5.0	5.0	5.0
Betaine 5M	7.5	7.5	7.5
GoTaq 5u/ μ l	0.1	0.1	0.1
Primer F 10uM	1.0	1.0	1.0
Primer R 10uM	1.0	1.0	1.0
DMSO 100%	-	1.3	1.3
DNA	50-200 ng	50-200 ng	50-200 ng
H ₂ O	up to 25 μ L	up to 25 μ L	up to 25 μ L

Table 5. PCR thermal cycling conditions

t (°C)	Time (sec)	Cycles
95°C	7'	
95°C	1'	14
63°C – 0.5°C/cycle	1'	
72°C	1'	
95°C	1'	35
56°C	1'	
72°C	1' + 20''/cycle	
72°C	10'	

Main peaks = Full annealing



Stutter bands = Repeat annealing




Figure 2




Figure 3

